MEDICAL SERVICES

Departments

Languages

  • English

EDUCATION

Undergraduate Degree

  • Queen's University , 1983 , Kingston, Ontario , Canada

Medical School

  • University of British Columbia , 1987 , Vancouver, British Columbia , Canada

Internship

  • University of Western Ontario , 1988 , London, Ontario , Canada

Residency

  • University of Toronto , 1991 , Toronto, Ontario , Canada

Fellowship

  • Johns Hopkins Hospital , 1994 , Baltimore , MD

CERTIFICATIONS

  • American Board of Pathology, Anatomic

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma. Am J Surg Pathol. 2021 12 01; 45(12):1648-1660. View abstract
  2. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia. Gastroenterology. 2021 Oct 29. View abstract
  3. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology. 2018 07; 155(1):156-167. View abstract
  4. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist. 2017 01; 22(1):107-114. View abstract
  5. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome. Hum Pathol. 2016 Mar; 49:1-9. View abstract
  6. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract. Arch Pathol Lab Med. 2012 May; 136(5):496-503. View abstract
  7. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011 Aug 10; 29(23):3153-62. View abstract
  8. Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res. 2012 Apr; 173(2):320-6. View abstract
  9. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21. View abstract
  10. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15(6):2116-22. View abstract
  11. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10; 27(11):1814-21. View abstract
  12. Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol. 2009 Feb; 33(2):309-12. View abstract
  13. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 01; 15(1):338-45. View abstract
  14. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19372-7. View abstract
  15. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4. View abstract
  16. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer. 2008 Jul 15; 113(2):302-14. View abstract
  17. Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk. Dis Colon Rectum. 2008 Oct; 51(10):1467-73; discussion 1473-4. View abstract
  18. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008 Jun 10; 5(6):e123. View abstract
  19. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008 Jun; 32(6):936-42. View abstract
  20. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):21-31. View abstract
  21. Hyperplastic/serrated polyposis in inflammatory bowel disease: a case series of a previously undescribed entity. Am J Surg Pathol. 2008 Feb; 32(2):296-303. View abstract
  22. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res. 2007 Nov 15; 67(22):10736-43. View abstract
  23. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am J Surg Pathol. 2007 Nov; 31(11):1733-41. View abstract
  24. Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases. Am J Surg Pathol. 2007 Aug; 31(8):1238-45. View abstract
  25. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007 Jul; 133(1):48-56. View abstract
  26. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res. 2007 Mar 01; 67(5):2366-72. View abstract
  27. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84. View abstract
  28. Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res. 2006 Jun 15; 66(12):6432-8. View abstract
  29. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006 Apr 11; 103(15):5947-52. View abstract
  30. Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res. 2006 Feb 15; 312(4):387-400. View abstract
  31. Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer. 2006 Feb 01; 106(3):693-702. View abstract
  32. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol. 2006 Feb 20; 24(6):878-83. View abstract
  33. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 2006 Jan 01; 66(1):95-106. View abstract
  34. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006 Jan; 126(1):154-60. View abstract
  35. Tumor microsatellite instability in early onset gastric cancer. J Mol Diagn. 2005 Oct; 7(4):465-77. View abstract
  36. Basal cell carcinoma with matrical differentiation: a case study with analysis of beta-catenin. J Cutan Pathol. 2005 Mar; 32(3):245-50. View abstract
  37. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg. 2005 Mar; 241(3):491-6. View abstract
  38. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J Cutan Pathol. 2005 Feb; 32(2):148-57. View abstract
  39. Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse. Cancer Res. 2005 Feb 01; 65(3):1097-104. View abstract
  40. Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon. Hum Pathol. 2005 Jan; 36(1):101-11. View abstract
  41. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development. 2005 Jan; 132(2):415-27. View abstract
  42. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis. 2005 Mar; 26(3):587-95. View abstract
  43. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst. 2004 Nov 03; 96(21):1631-4. View abstract
  44. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol. 2004 Nov; 11(11):977-82. View abstract
  45. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg. 2004 Oct; 240(4):624-8; discussion 628-30. View abstract
  46. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res. 2004 Sep 15; 64(18):6402-9. View abstract
  47. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem. 2004 Oct 08; 279(41):43261-72. View abstract
  48. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A. 2004 Jun 15; 101(24):9067-72. View abstract
  49. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004 Jun; 127(6):1579-86. View abstract
  50. Successful treatment of cap polyposis with infliximab. Gastroenterology. 2004 Jun; 126(7):1868-71. View abstract
  51. Chromosome 7q31 allelic imbalance and somatic mutations of RAY1/ST7 gene in colorectal cancer. Cancer Lett. 2004 Jan 08; 203(1):87-90. View abstract
  52. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003 Dec 15; 17(24):3112-26. View abstract
  53. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003 Jul 17; 349(3):247-57. View abstract
  54. Hereditary nonpolyposis colorectal cancer--molecular basis. Surgery. 2003 Jul; 134(1):29-33. View abstract
  55. Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res. 2003 Apr 15; 63(8):1769-71. View abstract
  56. Assembling a tumor progression model. Methods Mol Biol. 2003; 223:383-401. View abstract
  57. Multi-detector row helical CT in preoperative assessment of small (< or = 1.5 cm) liver metastases: is thinner collimation better? Radiology. 2002 Oct; 225(1):137-42. View abstract
  58. Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. J Clin Endocrinol Metab. 2002 Jul; 87(7):3078-83. View abstract
  59. Mutation profiling of mismatch repair-deficient colorectal cncers using an in silico genome scan to identify coding microsatellites. Cancer Res. 2002 Mar 01; 62(5):1284-8. View abstract
  60. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002 Feb 15; 20(4):1043-8. View abstract
  61. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res. 2001 Aug 15; 61(16):6131-6. View abstract
  62. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. Gastroenterology. 2001 Aug; 121(2):275-81. View abstract
  63. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2001 May 02; 93(9):700-4. View abstract
  64. Adenomatous polyps develop commonly in the ileal pouch of patients with familial adenomatous polyposis. Dis Colon Rectum. 2001 Mar; 44(3):347-53. View abstract
  65. Carcinogenesis in the GI tract: from morphology to genetics and back again. Mod Pathol. 2001 Mar; 14(3):236-45. View abstract
  66. P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Res Treat. 2001 Jan; 65(2):111-8. View abstract
  67. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature. 2000 Aug 24; 406(6798):897-902. View abstract
  68. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol. 2000 May; 156(5):1641-51. View abstract
  69. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer. 2000 Apr; 27(4):358-61. View abstract
  70. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res. 2000 Jan 15; 60(2):409-16. View abstract
  71. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000 Jan 13; 342(2):69-77. View abstract
  72. A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening. J Med Genet. 1999 Oct; 36(10):790-3. View abstract
  73. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol. 1999 Oct; 23(10):1248-55. View abstract
  74. STK11/LKB1 germline mutations are not identified in most Peutz-Jeghers syndrome patients. Clin Genet. 1999 Aug; 56(2):136-41. View abstract
  75. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 1999 Jul 15; 59(14):3346-51. View abstract
  76. Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet. 1999 May; 8(5):823-9. View abstract
  77. Family history characteristics, tumor microsatellite instability and germline MSH2 and MLH1 mutations in hereditary colorectal cancer. Hum Genet. 1999 Feb; 104(2):167-76. View abstract
  78. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet. 1999 Feb; 64(2):378-84. View abstract
  79. Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer. Int J Cancer. 1998 Nov 23; 78(5):600-5. View abstract
  80. Somatic instability of the APC I1307K allele in colorectal neoplasia. Cancer Res. 1998 Sep 15; 58(18):4040-3. View abstract
  81. The APCI1307K allele and breast cancer risk. Nat Genet. 1998 Sep; 20(1):13-4. View abstract
  82. Analysis of mRNA from microdissected frozen tissue sections without RNA isolation. Am J Pathol. 1998 Jul; 153(1):47-51. View abstract
  83. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol. 1998 Apr; 51(2):71-9. View abstract
  84. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res. 1998 Feb 15; 58(4):785-9. View abstract
  85. Molecular biology of colorectal cancer. Curr Probl Cancer. 1997 Sep-Oct; 21(5):233-300. View abstract
  86. The diagnostic challenge of vasculitis in a patient presenting with acute cholecystitis and a focal pancreatic mass: case report. Can Assoc Radiol J. 1997 Jun; 48(3):179-82. View abstract
  87. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet. 1997 May; 16(1):17-8. View abstract
  88. Adenomyoma of the common bile duct imaged with endoscopic ultrasonography: case report. Can Assoc Radiol J. 1997 Apr; 48(2):101-4. View abstract
  89. Using genetic information to make surgical decisions: report of a case of a 13-year-old boy with colon cancer. Dis Colon Rectum. 1997 Feb; 40(2):240-3. View abstract
  90. Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res. 1996 Aug 15; 56(16):3842-9. View abstract
  91. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res. 1996 Jul 01; 56(13):2922-6. View abstract
  92. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. Mod Pathol. 1996 Mar; 9(3):233-7. View abstract
  93. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res. 1995 Oct 15; 55(20):4670-5. View abstract
  94. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 1995 Oct; 147(4):884-8. View abstract
  95. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet. 1995 Sep; 11(1):64-70. View abstract
  96. A preventive registry for hereditary nonpolyposis colorectal cancer. Can J Oncol. 1995 Jul; 5(2):355-60. View abstract
  97. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology. 1995 Feb; 108(2):383-92. View abstract
  98. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994 Sep; 8(1):27-32. View abstract
  99. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology. 1994 Aug; 107(2):420-8. View abstract
  100. Klenow co-sequencing: a method for eliminating "stops". Biotechniques. 1994 Aug; 17(2):286, 288. View abstract
  101. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994 Jul 01; 54(13):3568-73. View abstract
  102. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994 Jun 01; 54(11):3025-33. View abstract
  103. Allelotype of pancreatic adenocarcinoma. Cancer Res. 1994 May 15; 54(10):2761-4. View abstract
  104. The effect of inhibitors of endogenous opioid degradation, bacitracin, bestatin, captopril, and D-phenylalanine, on digoxin-induced arrhythmias in guinea pigs. Can J Physiol Pharmacol. 1989 Aug; 67(8):857-63. View abstract